SAR3419 in Acute Lymphoblastic Leukemia

• Status: Terminated
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

Participants achieving an Objective Response Rate

Secondary Objectives:

• Response duration

• Progression Free Survival

• Minimal residual disease

• Safety

• Pharmacokinetics

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Maytansine

Criteria

Inclusion criteria:

• Previously treated Acute Lymphoblastic Leukemia of B cell origin (including Burkitt's lymphoma) in relapse or primary refractory. Patients in first relapse will be eligible regardless of the first remission duration.

• No more than 3 prior salvage therapies.

• Philadelphia positive patients failing treatment with imatinib mesylate are accepted.

• CD19 positive patients.

Exclusion criteria:

None

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.